Intec reaches deal with LTS Lohmann to manufacture its Parkinson’s drug candidate

Parkinson's brain cell
A Lewy body in a brain cell of the substantia nigra in Parkinson's disease. (By Marvin 101 (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons)

Intec Pharma, the maker of the Accordion delivery platform, is partnering with LTS Lohmann Therapie-Systeme of Germany to manufacture its lead drug candidate Accordion Pill carbidopa/levodopa, designed to treat severe symptoms in advanced cases of Parkinson’s disease.

Israel-based Intec is currently manufacturing the drug at its facility in Jerusalem. Under terms of the partnership, LTS will produce the AP-CD/LD capsules at its facility in Andernach, Germany, once the production line is completed, the company said. Financial terms of the partnership weren’t disclosed.

“This is a key achievement for Intec as we near completion of our pivotal Phase 3 Accordance clinical trial in advanced Parkinson's Disease patients and advance our pre-commercial strategies for AP-CD/LD," Jeffrey Meckler, Intec’s chief executive, said in a statement.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Intec’s Accordion platform is a gastroretentive delivery system designed to improve the absorption of poorly soluble drugs in the gastrointestinal tract. The technology incorporates a biodegradable polymeric film folded into a regular capsule. When released, the structure unfolds into an accordion shape and can be retained in the stomach for up to 12 hours, releasing the contained drug there in a more controlled manner than by oral consumption alone.

RELATED: Intec pulls in $5.2M Israeli grant for Parkinson's oral candidate

In addition to the Parkinson’s candidate, which delivers a combination of carbidopa and levodopa to treat symptoms of the neurological disorder, Intec has also been working on a candidate to treat insomnia and one for treating ulcers in the bowel.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.